1. Home
  2. TBPH vs MEG Comparison

TBPH vs MEG Comparison

Compare TBPH & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Montrose Environmental Group Inc.

MEG

Montrose Environmental Group Inc.

HOLD

Current Price

$22.04

Market Cap

930.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
MEG
Founded
2013
2012
Country
United States
United States
Employees
N/A
3500
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
930.8M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
TBPH
MEG
Price
$13.86
$22.04
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$18.50
$35.25
AVG Volume (30 Days)
782.6K
449.7K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.69
EPS
0.88
N/A
Revenue
$15,386,000.00
$830,538,000.00
Revenue This Year
$70.90
$4.94
Revenue Next Year
N/A
$7.71
P/E Ratio
$15.75
N/A
Revenue Growth
N/A
19.26
52 Week Low
$7.90
$10.51
52 Week High
$21.03
$32.00

Technical Indicators

Market Signals
Indicator
TBPH
MEG
Relative Strength Index (RSI) 27.74 35.15
Support Level $13.41 $21.00
Resistance Level $14.76 $24.03
Average True Range (ATR) 0.58 1.34
MACD -0.08 -0.58
Stochastic Oscillator 11.29 0.00

Price Performance

Historical Comparison
TBPH
MEG

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.

Share on Social Networks: